Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; adjusted EPS per diluted share increased to $10.17
Board approves new $1 billion share repurchase program
DUBLIN, IRELAND, May 11, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7% to $1.6 billion compared with $1.5 billion in the fourth quarter of fiscal 2025. Constant currency organic revenue growth from continuing operations grew 5% in the fourth quarter.
Revenue from continuing operations for the full year fiscal 2026 increased 9% to $5.9 billion compared with $5.5 billion in fiscal 2025. Constant currency organic revenue growth from continuing operations grew 7% for fiscal 2026.
"Fiscal 2026 was another record year," said Dan Carestio, President and CEO of STERIS. "Our diversified Customer base and growth in procedure volumes continue to drive our performance. We appreciate the efforts of our global Associates who continue to put our Customers first. As we look ahead, we are excited for what is to come as we capitalize on our unique ability to help our Customers enable procedural growth, deliver quality outcomes and drive compliance with standardization and optimization."
Total Company Fourth Quarter and Full Year Results from Continuing OperationsAs reported, net income from continuing operations for the fourth quarter was $220.3 million or $2.24 per diluted share, compared with net income of $146.5 million or $1.48 per diluted share in the fourth quarter of fiscal 2025. Adjusted net income for the fourth quarter of fiscal 2026 was $278.3 million or $2.83 per diluted share, compared with the previous year's fourth quarter of $270.3 million or $2.74 per diluted share.
As reported, net income from continuing operations for the full year fiscal 2026 was $782.3 million or $7.93 per diluted share, compared with net income of $610.1 million or $6.16 per diluted share in fiscal 2025. Adjusted net income for the full year fiscal 2026 was $1.0 billion or $10.17 per diluted share, compared with $913.2 million or $9.22 per diluted share in fiscal 2025.
Fourth Quarter Segment Results Healthcare revenue as reported grew 7% in the fourth quarter to $1.14 billion compared with $1.06 billion in the fourth quarter of fiscal 2025. This performance reflected 9% improvement in service revenue, 7% growth in consumable revenue, and a 6% increase in capital equipment revenue. Constant currency organic revenue growth was 6%. Healthcare operating income was $283.2 million compared with $279.7 million in last year's fourth quarter. The increase in operating income was primarily due to improved volume and price, which were significantly offset by tariffs and inflation.
Fiscal 2026 fourth quarter revenue for Applied Sterilization Technologies (AST) increased 6% as reported to $289.2 million compared with $273.9 million in the same period last year. This performance reflected 10% growth in service revenue and a 62% decline in capital equipment revenue. Constant currency organic revenue growth was 2%. Segment operating income was $131.1 million in the fourth quarter of fiscal 2026, compared with operating income of $122.2 million in the same period last year. The operating income increase compared with the prior year primarily reflects improved price, which was partially offset by negative volume from capital equipment declines.
Life Sciences fourth quarter revenue as reported increased 9% to $162.9 million compared with $149.5 million in the fourth quarter of fiscal 2025. This performance reflected 19% growth in capital equipment, 8% growth in service revenue and 5% improvement in consumable revenue. Constant currency organic revenue increased 6%. Reflecting improvement in price and volume, somewhat offset by inflation and tariffs, operating income increased to $70.6 million in the fourth quarter of fiscal 2026 compared with $65.0 million in the prior year's fourth quarter.
Cash Flow Net cash provided by operations for fiscal 2026 was $1.34 billion, compared with $1.15 billion in fiscal 2025. Free cash flow for fiscal 2026 was $982.9 million compared with $787.2 million in the prior year period. ...
